Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2 publications
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.
Journal: Breast cancer research and treatment
Published: March 20, 2018
Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: September 29, 2016
Showing 1-2 of 2
Last Updated: 09/26/2026